Browsing by Subject ovarian cancer
Showing results 1 to 19 of 19
Issue Date | Title | Author(s) |
---|---|---|
16-Dec-2020 | Biomarker CA125 Feature Engineering and Class Imbalance Learning Improves Ovarian Cancer Prediction | Yang, X; Khushi, M; Shaukat, K |
7-Feb-2022 | Carbon nanotube-coated recombinant human surfactant protein D reduces cell viability in an ovarian cancer cell line, SKOV3, and modulates mTOR pathway and pro-inflammatory cytokine response | Alshaya, DS; Jalal, AS; Alburae, NA; Aljarba, NH; Murugaiah, V; Kishore, U; Al-Qahtani, AA |
31-Oct-2018 | Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry | Rogers‑Broadway, KR; Kumar, J; Sisu, C; Wander, G; Mazey, E; Jeyaneethi, J; Pados, G; Tsolakidis, D; Klonos, E; Grunt, T; Hall, M; Chatterjee, J; Karteris, E |
1-Feb-2022 | Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro | Filipe, A; Chudasama, D; Kerslake, R; Jeyaneethi, J; Anikin, V; Kyrou, I; Randeva, H; Sisu, C; Hall, M; Karteris, E |
8-Oct-2022 | Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer | Kerslake, R; Sisu, C; Panfilov, S; Hall, M; Khan, N; Jeyaneethi, J; Randeva, H; Kyrou, I; Karteris, E |
27-Apr-2024 | Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model | Morea, A; Saravi, S; Sisu, C; Hall, M; Tosi, S; Karteris, E; Storlazzi, CT |
2-Sep-2020 | H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival | Saravi, S; Katsuta, E; Jeyaneethi, J; Amin, HA; Kaspar, M; Takabe, K; Pados, G; Drenos, F; Hall, M |
21-Dec-2016 | Human C1q Induces Apoptosis in an Ovarian Cancer Cell Line via Tumor Necrosis Factor | Kaur, A; Sultan, SHA; Murugaiah, V; Pathan, AA; Alhamlan, F; Karteris, E; Kishore, U |
5-May-2021 | Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer | Zahra, A; Dong, Q; Hall, M; Jeyaneethi, J; Silva, E; Karteris, E; Sisu, C |
10-May-2022 | Impact of environmentally relevant concentrations of Bisphenol A (BPA) on the gene expression profile in an in vitro model of the normal human ovary | Zahra, A; Kerslake, R; Kyrou, I; Randeva, HS; Sisu, C; Karteris, E |
12-Sep-2019 | Kinase inhibitors and ovarian cancer | Katopodis, P; Chudasama, D; Wander, G; Sales, L; Kumar, J; Pandhal, M; Anikin, V; Chatterjee, J; Hall, M; Karteris, E |
8-Dec-2022 | A Meta-analysis of 2D vs. 3D Ovarian Cancer Cellular Models | Kerslake, R; Belay, B; Panfilov, S; Hall, M; Kyrou, I; Randeva, HS; Hyttinen, J; Karteris, E; Sisu, C |
9-Jul-2021 | A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer | Kerslake, R; Hall, M; Vagnarelli, P; Jeyaneethi, J; Randeva, HS; Pados, G; Kyrou, I; Karteris, E |
9-Feb-2012 | The peritoneal tumour microenvironment of high-grade serous ovarian cancer | Leinster, DA; Kulbe, H; Everitt, G; Thompson, R; Perretti, M; Gavins, FNE; Cooper, D; Gould, D; Ennis, DP; Lockley, M; McNeish, IA; Nourshargh, S; Balkwill, FR |
15-Sep-2021 | Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of Brca2 Status | Saravi, S; Alizzi, Z; Tosi, S; Hall, M; Karteris, E |
1-Mar-2016 | The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro | Mankarious, A; Dave, F; Pados, G; Tsolakidis, D; Gidron, Y; Pang, Y; Thomas, P; Hall, M; Karteris, E |
6-Jun-2024 | The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review | Hablase, R; Kyrou, I; Randeva, H; Karteris, E; Chatterjee, J |
9-Jul-2019 | Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer | Karteris, E; Kumar, J; Murugaiah, V; Sotiriadis, G; Kaur, A; Jeyaneethi, J; Sturniolo, I; Alhamlan, F; Chatterjee, J; Hall, M; Kishore, U |
26-Jun-2023 | Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models | Kerslake, R; Belay, B; Panfilov, S; Hall, M; Kyrou, I; Randeva, HS; Hyttinen, J; Karteris, E; Sisu, C |